HKPD vs NUS
Cellyan Biotechnology Co. Ltd. and NU Skin Enterprises, Inc., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | HKPD | NUS |
|---|---|---|
| Revenue | $20.3M | $1.5B |
| Net income | $-27,056 | $160.2M |
| Gross margin | 11.9% | 69.4% |
| Net margin | −0.1% | 10.8% |
| Return on equity | −0.6% | 22.0% |
| Diluted EPS | −$0.00 | $3.18 |
| Dividend / share | · | · |
| Payout ratio | · | 7.4% |
| Free cash flow | $499,298 | $46.0M |
| Equity | $5.0M | $805.2M |
| Net debt / equity | 0.23× | −0.02× |
| Current ratio | 2.99× | 2.08× |
| Revenue CAGR 5y | · | −10.5% |
| Profit CAGR 5y | · | −3.5% |
NUS bills 73.1× the revenue of HKPD, and HKPD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | HKPD | NUS |
|---|---|---|
| FY2024 | $20.3M | $1.7B |
| FY2023 | $16.7M | $2.0B |
| FY2022 | $12.6M | $2.2B |
Bottom line
| Fiscal year | HKPD | NUS |
|---|---|---|
| FY2024 | $-27,056 | $-146.6M |
| FY2023 | $1.3M | $8.6M |
| FY2022 | $998,196 | $104.8M |
Standard deviation, each side
NUS's net margin has been more volatile than HKPD's over the 3 comparable fiscal years — 5.5 percentage points of standard deviation against 3.8.
3 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
HKPD led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
HKPD's return on equity has been more volatile than NUS's over the 3 comparable fiscal years — 71.3 percentage points of standard deviation against 13.1.
3 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
HKPD led in return on equity in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 18 comparable fiscal years — a year missing data on either side is not counted.